ONCT - Oncternal Therapeutics, Inc. Price-to-Projected Revenue Ratio

Oncternal Therapeutics (ONCT) is expanding its influence by automating clinical data collection through cloud IT solutions. This chart on GURU.Markets shows that the projected P/S trend confirms business stability, where the value of 0.70 characterizes this level. Growth is driven by the success of zilovertamab and CAR-T therapy, while the optimization of antibody supplies ensures protection against logistical disruptions.

Oncternal Therapeutics Inc - ONCT Projected Price to Revenue (period 07/04/2022 - 12/14/2024)

Comprehensive metric breakdowns and analytics for Oncternal Therapeutics, Inc. (ONCT)

- market price and analyst price targets:

Price Chart Oncternal|ONCT - Price Target Chart

- market capitalization statistics:

Market Value Oncternal Corp|ONCT - Total Enterprise Value

- book value of equity indicators:

Book Value per Share Oncternal Therapeutics|ONCT - Book Value of Business|Market Cap to Net Assets Ratio oncternal.com|ONCT - Company Assets

- debt and liquidity data:

Total Debt to Equity Ratio Oncternal Therapeutics|ONCT - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity Ratio Oncternal Therapeutics|ONCT - Company Cumulative Indebtedness|Debts to Book Capitalization Oncternal Therapeutics Inc|ONCT - Company Long-Term Loans and Borrowings|Company Short-Term Debts Oncternal Therapeutics|Quick Liquidity oncternal.com

- financial results and valuation multiples details:

ONCT - Final Profit|Projected Future Earnings Oncternal Therapeutics|ONCT - P/E Multiple|Future Price to Earnings Oncternal|ONCT - Market Cap to Earnings and Growth Ratio|Enterprise Value to EBITDA Ratio Oncternal Corp|ONCT - Profit before interest, taxes and amortization|Earnings per share for the last twelve months Oncternal Therapeutics|ONCT - Net earnings per one share for the last twelve months|Year-over-year earnings per share growth for the last twelve months oncternal.com|ONCT - Earnings per share growth this year|Earnings growth forecast for next year Oncternal Therapeutics

- revenue and sales proceeds data:

ONCT - Company Sales|Company Future Sales Volume Oncternal Therapeutics, Inc.|ONCT - Market Cap to Sales Volume|Forward P/S Multiple Oncternal Corp

General company analysis:Oncternal ONCT

This indicator is calculated as the ratio of current market capitalization to projected revenue, measuring the growth rate of market value relative to expected cash flows. In the forward P/S valuation history for Oncternal Therapeutics (ONCT), this balance reflects market confidence in the commercialization of unique inhibitors, where the curve's dynamics allow for a distinction between a fair premium for patent potential and unjustified overvaluation.

Key competitors

Price-to-Projected Revenue Ratio Incyte Corp. INCY|HUTCHMED Ltd (HCM) - Market Cap to Future Revenue Ratio|NUVB - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio Day One|MNPR: Forward P/S Multiple|Projected Price to Revenue Inhibrx Biosciences Inc INBX|Forward Price-to-Revenue Multiple IMAB|Market Cap to Future Revenue Ratio Fennec Pharmaceuticals FENC|Forward Price-to-Revenue Multiple HRTX (Heron)|NVCT (Nuvectis Pharma) - Forward Price to Sales|Coherus Biosciences - Forward Price-to-Revenue Multiple|Price to Expected Revenue Ratio CRBP (Corbus Pharmaceuticals Holdings)|Cardiff Oncology - Forward P/S Multiple|Forward Price to Sales BYSI (BeyondSpring Pharma)|BCAB: Forward P/S Multiple|Market Cap to Future Revenue Ratio lixte.com (LIXT)|Price-to-Projected Revenue Ratio citiuspharma.com|CLRB: Forward Price to Sales|Forward P/S Multiple BLRX|Forward P/S Multiple Can-Fite (CANF)|Price-to-Projected Revenue Ratio Aprea Therapeutics Inc. APRE|KZIA (kaziatherapeutics.com) - Future Price to Revenue|SLXN: Forward Price-to-Revenue Multiple|Market Cap to Future Revenue Ratio NuCana|CMRX: Forward P/S Multiple|Forward Price-to-Revenue Multiple Cyclacel Pharmaceuticals|GTHX (g1therapeutics.com) - Forward P/S Multiple|KRON: Forward Price to Sales|Price-to-Projected Revenue Ratio Kintara (KTRA)|PRTG (Portage) - Forward Price to Sales